Jackson Mark R MR

Show results for

Unknown (29)
Proteomics (2)

Organisms

Andropogon gerardi (2)
Bacteria (2)
Botrytis cinerea (2)
Canis lupus familiaris (2)
Clostridium perfringens (2)
Cnidaria (2)
Cricetulus griseus (2)
Eukaryota (2)
Fasciola (2)
Hepatitis B virus (2)
Human betaherpesvirus 5 (2)
Japanese encephalitis virus group (2)
Madurella mycetomatis (2)
Mesocricetus auratus (2)
Miscanthus x giganteus (2)
Mycobacterium tuberculosis (2)
Orthoflavivirus (2)
Panicum virgatum (2)
Platyhelminthes (2)
Pseudomonas aeruginosa AES-1R (2)
Rickettsia (2)
Saccharomyces cerevisiae (2)
Schizosaccharomyces pombe (2)
Severe acute respiratory syndrome coronavirus 2 (2)
Sorghastrum nutans (2)
Streptococcus dysgalactiae subsp. equisimilis SK1249 (2)
Streptococcus pneumoniae (2)
Streptomyces coelicolor A3(2) (2)
Toxoplasma gondii (2)
Tripsacum dactyloides (2)

Repository

pride (2)

Tissue

B cell (1)
Bone marrow (1)
Brain (1)
Cell culture (1)
Spleen (1)

Disease

Acute leukemia (1)
Diffuse midline glioma (1)
Lymphoma (1)

Technology Type

Mass Spectrometry (2)
Gel-based experiment (1)
Shotgun proteomics (1)

Publication Date

2026 (1)
2023 (1)

Release Date

2024 (8)
2025 (5)
2023 (3)
2021 (3)
2019 (2)
2015 (2)
2022 (1)
2020 (1)
2018 (1)
2017 (1)
2016 (1)
2011 (1)

Lab affiliation

1. Cancer Signalling Research Group, School of Biomedical Sciences and Pharmacy, College of Health, Medicine and Wellbeing, University of Newcastle, Callaghan, NSW, AUSTRALIA 2. Precision Medicine Research Program, Hunter Medical Research Institute, New Lambton Heights, NSW, AUSTRALIA 3. Paediatric Program, Mark Hughes Foundation Centre for Brain Cancer Research, College of Health, Medicine, and Wellbeing, Callaghan, NSW, AUSTRALIA (1)
Yale University (1)

Previous page
1 / 4
You're on page 1
page 2
page 3
page 4
Next page

Sort by:

Relevance

Page size

Phase II study of aflibercept in recurrent malignant glioma: a North American Brain Tumor Consortium study.

Not available

S-EPMC3139373 | biostudies-literature

BioID of CD25 mutants in B-cell malignancies

CD25-dificient patient-derived PDX2 B-ALL cells and Jeko1 MCL cells with CRISPR-Cas9-mediated gene deletion were reconstituted with wild-type CD25 (S268) or CD25 carrying S268A mutant (A268) with C-terminal BirA (engineered biotin ligase) and selected by puromycin for 3 days. BirA expressing constru...

ORGANISM(S): Homo sapiens (Human)

2026-02-23 | PXD035989 | Pride

Generation of mice with combined Hexa Gly269Ser KI or KO and Neu3 KO alleles to create new models of GM2 gangliosidoses.

Not available

S-EPMC12519549 | biostudies-literature

Decitabine cytotoxicity is promoted by dCMP deaminase DCTD and mitigated by SUMO-dependent E3 ligase TOPORS

Not available

S-SCDT-10_1038-S44318-024-00108-2 | biostudies-other

ONC201 in combination with paxalisib for the treatment of H3K27-altered diffuse midline glioma

Diffuse midline gliomas (DMG), including diffuse intrinsic pontine gliomas (DIPGs), are the most lethal of all childhood cancers. Palliative radiotherapy is the only proven life-prolonging treatment, with patient survival 9-11 months. ONC201 shows preclinical and emerging clinical efficacy in DIPG. ...

ORGANISM(S): Homo sapiens (Human)

2023-05-25 | PXD036245 | Pride

Dmg Clpp agonist Targeted therapies Dipg Onc201

Systems serology detects functionally distinct coronavirus antibody features in children and elderly.

Not available

S-EPMC8016934 | biostudies-literature

Novel genetic loci underlying human intracranial volume identified through genome-wide association.

Not available

S-EPMC5227112 | biostudies-literature

Effect of remote ischaemic conditioning on clinical outcomes in patients with acute myocardial infarction (CONDI-2/ERIC-PPCI): a single-blind randomised controlled trial.

Not available

S-EPMC6891239 | biostudies-literature